Clinical Progress
Recent Developments
OUR COMPANY
Thetis is a clinical-stage pharmaceutical company developing first-in-class, oral TP-317 for inflammatory bowel disease (IBD) and solid tumors.
TP-317 MECHANISM
TP-317 is a Resolvin E1 (RvE1) drug that activates BLT1 — a GPCR expressed on epithelial and immune cells — to restore and maintain tissue and immune homeostasis.
Clinical Progress
In a Phase 1a healthy-volunteer study, oral TP-317 was well-tolerated and demonstrated BLT1 target engagement.
A 12-week Phase 1b study in moderate-to-severe ulcerative colitis patients is scheduled to begin in the second half of 2026, incorporating epithelial repair, fibrosis, and clinical, endoscopic, and histopathological response as exploratory readouts.
Recent Developments